INTRODUCTION
Stem cells are primitive cells with the potential to self-renew and differentiate, and they can be transplanted into the vascular system, where they home to injury sites by circulating through the blood to regenerate new tissue [1] [2] [3] . Based on these discoveries, stem cell therapy has emerged as a primary focus of regenerative medicine research. Duchenne muscular dystrophy (DMD) is a genetic disease caused by mutations in the dystrophin gene [4] . Stem cell therapy is a promising new therapeutic strategy in the treatment of DMD, as an effective treatment requires the delivery of wild-type dystrophin protein to the muscles of the entire body. Our previous studies [3] [4] [5] have demonstrated that mesenchymal stem cells injected into the tail vein of DMD model mice home to striated muscle and restore rat dystrophin protein and mRNA expression, as assayed by immunofluorescence and RT-PCR, respectively. It has also been shown that allogeneic transplantation or xenotransplantation of mesenchymal stem cells does not cause significant immunological rejection [3] [4] [5] [6] [7] . The mdx mouse is a DMD model widely used to examine in vivo stem cell differentiation potential. Embryonic stem cells have full differentiation potential in vivo, while pluripotent stem cells express a portion of embryonic stem cell markers and have been the focus of stem cell therapy [7, 8] . The successful generation of induced pluripotent stem (iPS) cells by viral expression of transcription factors marked an important breakthrough in stem cell research [9] . However, iPS cells have tumorigenic potential, limiting their wide clinical application. Therefore, safer and more efficient reprogramming methods have been explored. The initial cloning study of Dolly the sheep demonstrated that certain factors play important roles in somatic cell reprogramming in oocytes [10] . Enlightened by this study, we have successfully reprogrammed skin fibroblasts into induced multipotent stem (iMS) cells by co-culturing the fibroblasts in DMEM/F12 medium containing 10% fetal bovine serum with fish oocyte extract (FOE) [11, 12] . We found that the serum-free culture system helped maintain multipotent stem cells' stemness [13] . Future studies will focus on the impact of serum-free culture on co-cultured fibroblasts with FOE and the in vitro and in vivo multipotency of FOE-treated fibroblasts. In this study, we treated adult human fibroblasts with FOE and examined their ability to become multipotent. Their stem cell marker expression and in vitro and in vivo multipotency were analyzed, and we found that FOE induced Oct-4, Nanog-3 and SSEA-4 expression in fibroblasts. Furthermore, FOE-treated fibroblasts could be induced to become adipogenic, osteoblastic or myogenic in vitro. Human dystrophin expression was detected in irradiated mdx mice transplanted with FOE-treated fibroblasts. However, FOE-treated fibroblast transplantation did not significantly improve the DMD muscle phenotype in mdx mice.
MATERIALS AND METHODS

FOE and fibroblast co-culture
All experiments were conducted according to the protocol (No. 0000083) approved by the Animal Committee of the Animal Center of Kunming General Hospital. Human fibroblasts were prepared as described previously [9] . Briefly, circumcised adult foreskins were collected from Kunming General Hospital and cut into small pieces, then digested step-wise with 200 U/ml collagenase (all chemicals were from Invitrogen unless otherwise stated, Invitrogen, Grand Island, NY, USA), 300 U/ml hyaluronidase, 0.25% trypsin and 0.02% EDTA (Sigma, St. Louis, MO, USA). The cells were rinsed and transferred into a culture flask containing DMEM/F12 plus 10% fetal bovine serum (FBS) at 37°C with 5% CO 2 and 90% humidity. The medium was changed every 2-3 days. Cells were passaged once they became confluent. FOE was prepared as described previously [11] . Briefly, fish oocytes were collected and extracted with an equal volume of 0.9% sodium chloride. After centrifugation at 1000 rpm for 10 min and twice at 4000 rpm for 30 min, supernatants were collected and filtered using 0.22 μm filters (Millipore, MA, USA). Protein levels were determined by Bradford assay and adjusted to 1.2 mg/ml with Knockout DMEM supplemented with 20% serum replacement (SR), 2 mM L-glutamine, 1% non-essential amino acids (NEAA), 0.1 mM 2-mercaptoethanol (Sigma) and 5 ng/ml basic fibroblast growth factor (bFGF) (Cell Systems, Remagen, Germany). We induced reprogramming as described previously [11, 12] . Passage 3 human fibroblasts were resuspended in DMEM/F12 containing 10% FBS and plated into a six-well plate or culture flask. After two days, the DMEM/F12 medium was replaced with serum-free Knockout DMEM medium containing 1.2 mg FOE/ml at 37°C for 72 h. Stem cell marker expression of the FOE-treated fibroblasts was analyzed by immunofluorescence staining and flow cytometry. Control fibroblasts (untreated fibroblasts) were cultured in serum-free medium only.
In vitro differentiation assay
After co-culture with FOE, the resultant reprogrammed fibroblasts were used for in vitro differentiation assays as described previously [13, 14] . To assess adipogenic differentiation, the serum-free medium was replaced with adipogenic medium (Miltenyi, Bergisch Gladbach, Germany) for 21 days in a six-well plate, and the medium was replaced every 3-4 days. Adipogenesis was assessed by Oil red O staining (Miltenyi). For osteogenic differentiation, the serum-free medium was replaced with osteogenic medium (Miltenyi) for 21 days in a six-well-plate, and the medium was replaced every 3-4 days. Cultures were stained with Alizarin Red S (Miltenyi) to check for a mineralized hydroxyapatite extracellular matrix. To assess for myogenic differentiation, serum-free medium was replaced with myogenic medium (Lonza, Basel, Switzerland) for ten days in a six-well plate, and the medium was replaced every 3-4 days. The cells were immunostained for myogenin and myosin heavy chain (MHC) as described previously [14] . Briefly, cells were incubated with mouse-anti-human myogenin and MHC, and incubated with a secondary HRP-conjugated rabbit/mouse antibody (Gene, USA). After staining with hematoxylin and eosin (H&E), the cells were photographed with an Olympus microscope (BX41TF, Olympus, Tokyo, Japan).
In vivo fibroblast transplantation
Six-week-old mdx mice were used for cell transplantation experiments. Mdx mice were sublethally irradiated with 6.5 Gy gamma rays and housed under specific-pathogen-free (SPF) conditions in individually ventilated cages. Two million FOE-treated fibroblasts (in 0.5 ml of saline) were injected into each of five mice via the tail vein at three days after irradiation. Five control mice were injected with an equal number of FOE-untreated fibroblasts (in 0.5 ml of saline) via the tail vein. Tissues were harvested two months after injection. The motor function of all mice was investigated as described previously [3] . Briefly, for the traction test, each mouse was placed on a steel wire for a total of 5 min and placed back on the wire if they fell. The total number of falls and the time spent on the wire were recorded. For the rotating rod test, mice were placed on a rod that rotated at 16 rotations/min for a total of 10 min. Mice were replaced on the rod if they fell. The total number of falls and the time spent on the rod were recorded. For the running wheel test, mice were placed on a running wheel and allowed to continuously run for 2 h. The total number of rotations during this period was recorded.
Creatine kinase (CK) activity assay Two months after transplantation, 1 ml of blood was collected from the orbital sinus into a tube. Serum was obtained by centrifuging the blood sample at 850 x g for 5 min. Serum CK activity was measured using the NADPH fluorescence kit (Roche, Basel, Switzerland) and spectrophotometry. CK activity was reported as IU per liter.
Immunofluorescence staining
Cells were grown in six-well plates and fixed in 4% paraformaldehyde. Nonspecific binding was blocked with goat serum (Boster, Wuhan, China) at room temperature for 1 h. Primary antibodies against mouse-anti-human Nanog-3, Oct-4 and SSEA-4 (Santa Cruz, Dallas, TX, USA) were applied overnight at 4°C. After washing, cells were incubated with FITC-conjugated secondary antibody at room temperature for 1 h. Nuclei were stained with DAPI (Sigma). Stained cells were examined under a Nikon fluorescence microscope (ECLIPSE 80i, Nikon, Tokyo, Japan). Muscle sections were first treated in 2 N HCl for 1 h. The primary antibody used was mouse anti-human dystrophin. The subsequent steps were the same as above.
Flow cytometry FOE-treated fibroblasts or control fibroblasts were incubated with FITC-conjugated antibodies against Nanog-3, Oct-4 and SSEA-4 (Santa Cruz) for 30 min. After washing, the cells were resuspended in buffer containing 4% paraformaldehyde for 15 min and analyzed on a FACScan with CellQuest software (Becton Dickinson, San Jose, CA, USA).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from gastrocnemius muscle using TRIzol reagent according to the manufacturer's instructions. First-strand cDNA was produced from 1 μg RNA using the Superscript III reverse transcription kit. RT-PCR was performed with 50 ng cDNA. The following PCR protocol was used: 95°C for 5 min; 40 cycles of 94°C for 30 s, 59°C for 30 s, and 72°C for 30 s; 72°C for 10 min. Primer pairs for human dystrophin were as follows: forward, 5'-CAGTAGCCCCATCACATTTG-3' and reverse, 5'-ATAACGCAATGGAC AATGGG-3'. cDNA prepared from human fetal skeletal muscle biopsies was used as a positive control, and ultrapure water was used as a negative control. PCR products were resolved by electrophoresis in a 1% agarose gel containing ethidium bromide and photographed under UV light.
Histological analysis of skeletal muscles
Gastrocnemius muscle sections were prepared as described above and stained with H&E. Images were acquired with an Olympus BX41TF microscope (Olympus, Tokyo, Japan). To obtain the percentage of myofibers with centrally localized nuclei, we counted myofibers in four representative muscle sections from each muscle sample. The central nucleation percentage was calculated according to the following formula: centrally nucleated myofibers (CNF; %) = number of myofibers with centrally localized nuclei/total myofiber number.
Statistical analysis
Data were reported as mean ± standard deviation (SD) and were analyzed with SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). Student's t-test was used to compare inter-group differences. A p-value less than 0.05 was considered statistically significant.
RESULTS
FOE treatment induces fibroblasts to become iMS cells
Spindle-shaped human fibroblasts were isolated from circumcised adult foreskin. Upon culture in serum-free medium, they became slender. When FOE was added to the medium, the cells became slightly larger (Fig. 1A, B, C) . Immunofluorescence staining demonstrated that a portion of FOE-treated fibroblasts expressed nuclear Nanog-3 and Oct-4 and cytoplasmic SSEA-4 ( Fig. 1D, E, F) . In contrast, we did not detect Nanog-3, Oct-4 or SSEA-4 staining in untreated fibroblasts (data not shown). Flow cytometry analysis further confirmed the expression of multipotent stem cell markers in FOE-treated fibroblasts. The percentage of cells expressing Oct-4, Nanog-3 and SSEA-4 was 15%, 8% and 21%, respectively (Fig. 1G) . These results suggest that some FOE-treated fibroblasts were reprogrammed into iMS cells.
FOE-treated fibroblasts are multipotent in vitro
To confirm that FOE-treated fibroblasts had become multipotent, we investigated their in vitro differentiation capabilities. When exposed to an adipogenic stimulus, the programmed fibroblasts displayed a neutral lipid droplet in the cytoplasm (Fig. 2A) . Likewise, when exposed to an osteoblastic stimulus, the programmed fibroblasts produced mineralized hydroxyapatite extracellular matrix (Fig. 2B ). When exposed to myogenic medium, the cells expressed the muscle-specific marker MHC and myogenin (Fig. 2C, D) . Taken together, these results confirm that FOE-treated fibroblasts are multipotent.
FOE-treated fibroblasts do not improve mouse motor function or reduce CK activity
Because FOE-treated fibroblasts were multipotent in culture, we aimed to determine whether they maintained this capacity in vivo. Thus, we transplanted FOE-treated cells into mdx mice and assessed their motor function. Compared to control mice transplanted with untreated fibroblasts, we found no significant improvement of motor function or immune rejection in mice injected with FOE-treated fibroblasts. To assess whether FOE-treated fibroblasts reduced DMD-associated muscle damage, we measured serum CK levels. We found that the CK level slightly decreased two months after cell transplantation (Fig. 3) , but there was no significant difference between mice transplanted with FOE-treated fibroblasts and untreated control fibroblasts. Fig. 1 . Characterization of human fibroblasts in different culture media. Human fibroblasts were isolated from circumcised adult foreskin and passaged in DMEM/F12 medium containing 10% fetal bovine serum (FBS). Passage 3 fibroblasts were cultured in serum-free medium (Knockout DMEM supplemented with SR, L-glutamine, NEAA, 2-mercaptoethanol, bFGF) or serum-free medium supplemented with 1.2 mg/ml fish oocyte extract (FOE) for 72 h. Phase-contrast images were acquired. Fibroblasts cultured in serumfree medium supplemented with 1.2 mg/ml FOE for 72 h were analyzed by immunofluorescence staining and flow cytometry. A -Fibroblasts cultured in serum-free medium plus 1.2 mg/ml FOE appeared slightly larger than fibroblasts in serum-free medium alone. B -Fibroblasts in serum-free medium alone were more slender than fibroblasts in DMEM/F12 medium containing 10% FBS. C -Fibroblasts in DMEM/F12 medium containing 10% FBS appeared flat. The scale bar in A-C is 100 μm. D -Merged image: blue, DAPI; green, Oct-4. (D1) Nuclear Oct-4 expression. E -Merged image: blue, DAPI; green, Nanog-3. E1 -Nuclear Nanog-3 expression. The scale bar in D-E1 is 40 μm. F -Cytoplasmic SSEA-4 expression in cytoplasm; note the absence of nuclear signal (scale bar = 20 μm). G -Fibroblasts cultured in serum-free medium supplemented with 1.2 mg/ml FOE for 72 h were subjected to FACS analysis for Oct-4, Nanog-3 and SSEA-4. The black lines show the fluorescence intensity of the IgG negative control antibody, whereas the intensity of the antibody of interest is shown in green. 
Human dystrophin is expressed in mdx mice after transplantation
We further investigated whether human dystrophin was expressed in the skeletal muscle of mdx mice transplanted with FOE-treated fibroblasts. We first stained skeletal muscle sections against human dystrophin and found that there were human dystrophin-expressing myofibers in mdx mouse muscles (Fig. 4A) , whereas control mouse muscle did not express human dystrophin (Fig. 4B) . Secondly, we used RT-PCR to analyze human dystrophin mRNA levels in mdx mouse skeletal muscle and confirmed that human dystrophin was expressed in FOE-treated fibroblast-transplanted mice, but not control mice (Fig. 4C) . These results indicate that transplanted programmed fibroblasts integrated into mdx mouse skeletal muscle, where they expressed human dystrophin. Fig. 3 . FOE-treated fibroblasts slightly reduce creatine kinase (CK) activity of mdx mice. FOE-treated fibroblasts (Transplantation) or untreated fibroblasts (Control) were transplanted into irradiated mdx mice via the tail vein. Two months after transplantation, serum CK activity was measured. * NS (not significant) vs. control group. Fig. 4 . FOE-treated fibroblasts express human dystrophin in mdx mouse skeletal muscle. Untreated or FOE-treated fibroblasts were transplanted into irradiated mdx mice. Two months after transplantation, gastrocnemius muscles were harvested and analyzed for human dystrophin expression by immunofluorescence staining and RT-PCR. In (A) and (B), human dystrophin is in green. A -Mdx mouse muscle transplanted with FOE-treated human fibroblasts and B -control mdx mouse muscle transplanted with untreated human fibroblasts. Note the human dystrophin-positive myofibers in (A) (scale bar = 40 μm) and only a background signal in (B) (scale bar = 40 μm). C -RT-PCR for human dystrophin. M, molecular marker; 1, muscle from control mdx mouse transplanted with untreated fibroblasts; 2, muscle from mdx mouse transplanted with FOE-treated fibroblasts; 3, human muscle; 4, ultrapure water as a negative control; 5, GAPDH as an internal control. Programmed fibroblasts slightly improve skeletal muscle histology Finally, we asked whether transplantation of programmed fibroblasts could improve skeletal muscle histology of mdx mice. Two months after cell transplantation, we harvested the gastrocnemius muscles and stained sections with H&E. In the muscles of C57BL/10 wild-type mice, myofibers were polygonal and uniform in size, and their nuclei were peripherally localized (Fig. 5A) . In contrast, in the muscle of mdx mice transplanted with FOE-untreated fibroblasts, myofibers varied in size and most myofibers had central nuclei. Inflammatory infiltration and interstitium were obvious (Fig. 5B) . In the muscles of mdx mice transplanted with FOE-treated fibroblasts, the myofiber size and CNF slightly improved (Fig. 5C ), but there was no significant difference between control mdx mice and FOE-treated fibroblast-transplanted mdx mice. Furthermore, the percentage of mdx mouse myofibers with central nuclei after FOE-treated fibroblast transplant was not significantly lower than the percentage in mdx mice transplanted with FOE-untreated fibroblasts (Fig. 5D ).
DISCUSSION
Somatic cell reprogramming into a pluripotent state has great therapeutic potential in regenerative medicine, as it bypasses the ethical issues associated with embryonic stem cell isolation and use and host rejection. In this study, we were able to improve upon our previous studies [12] to generate induced multipotent stem (iMS) cells expressing several stem cell markers, including Oct-4, Nanog-3 and SSEA-4, by co-culturing human fibroblasts with FOE in serum-free medium. These stem cells had a thinner morphology compared to fibroblasts and could be induced to differentiate into adipogenic, osteogenic and myogenic cells in vitro. It is clear that the serum-free conditions likely play an important role in supporting multipotent marker expression. Serum-free culture conditions may be favorable for maintaining the expression of stem cell markers [14] , and this has been confirmed in other studies [15] . So far, how to maintain primitive cells stemness has been still a focus [16] . Our results also indicate that the FOE-induced method is simple and can also be improved upon to increase multipotent marker expression. We further investigated the iMS cells' in vivo myogenic differentiation potential and therapeutic effect. The mdx mouse model of DMD does not express dystrophin, and it is an ideal model for evaluating the in vivo regenerative capacity of stem cells. Because FOE-treated fibroblasts contained a mixed population of cells, we transplanted two million cells into irradiated mdx mice. We found no significant immune rejection, as the leukocyte ratio was very low in mdx mice three days after irradiation with 6.5 Gy. At this time point, FOE-treated fibroblast transplantation should not result in a strong immune response. Two months after transplantation, we did not detect any human dystrophin expression in control mdx mice transplanted with untreated fibroblasts. Unexpectedly, CK activity and the percentage of myofibers with centrally localized nuclei after FOE-treated fibroblast transplantation only slightly decreased. However, human dystrophin was indeed expressed in mdx mice transplanted with FOE-treated fibroblasts. Our data suggest that the transplanted FOE-treated fibroblasts contained iMS cells, although they did not affect mouse motor function. One potential explanation is that there were an insufficient number of iMS cells among the transplanted fibroblasts to integrate into the gastrocnemius muscle. Although fibroblast reprogramming into iMS cells has been previously reported [11] , the percentage of fully functional iMS cells among 2 million FOE-treated fibroblasts transplanted may still not be enough. We suggest that the therapeutic effect of FOE-treated fibroblasts would improve if more FOE-treated fibroblasts were transplanted or if purified iMS cells derived from FOE-treated fibroblasts were transplanted. In fact, iPS cells have demonstrated dose-dependent stable therapeutic effects in chimeric mice with beta-thalassemia [17] . Human dystrophin expression in FOE-treated fibroblast-transplanted mdx mice was detected, indicating that reprogrammed cells were present, and such cells expressed multipotent markers, integrated into the injury site, and expressed dystrophin in mice. Thus, reprogrammed cells showed normal stem cell characteristics, which was consistent with recent studies [18] . Additionally, we confirmed that FOE-treated fibroblasts can differentiate into myofiber-expressed MHC and myogenin in myogenic medium, but few positive myofibers were detected in vitro by immunostaining, suggesting that the regenerative capacity of FOE-treated fibroblasts may be low. Notably, somatic cell reprogramming is an epigenetic event because the DNA beneath epigenetic marks/modifications remains largely unaltered [19] . Although we confirmed the expression of Oct-4, Nanog-3 and SSEA-4, it is not clear how FOE-treated fibroblasts relate to very small embryonic-like stem cells and iPS cells [20] . Thus, a promising strategy will be to transplant larger quantities of FOE-treated fibroblasts into DMD patients, although it is necessary to elucidate the exact molecular mechanisms and attempt to reprogram fibroblasts into very small embryonic-like stem cells or iPS cells.
